Skip to search formSkip to main contentSkip to account menu

omacetaxine

National Institutes of Health

Related topics

Related topics

2 relations
omacetaxine mepesuccinateomacetaxine mepesuccinate 3.5 MG Injection [Synribo]

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
Hydroxycoumarin OT-55 kills CML cells alone or in synergy with imatinib or Synribo: Involvement of ER stress and DAMP release.
Review
2017
Review
2017
Current approach to the treatment of chronic myeloid leukaemia.
Review
2016
Review
2016
Treatment of chronic myelogenous leukemia.
PURPOSE Treatment options for chronic-phase chronic myelogenous leukemia (CML) based on medication-resistant mutations in BCR-ABL… 
Review
2014
Review
2014
BCR-ABL inhibitors: Updates in the management of patients with chronic-phase chronic myeloid leukemia
Abstract Objectives This article reviews recent clinical experiences with first-line and second-line second-generation BCR-ABL… 
2012
2012
Undetectable molecular residual disease after omacetaxine and nilotinib combination therapy in an imatinib‐resistant chronic myeloid leukaemia patient harbouring the BCR‐ABL1 T315I gatekeeper…
John G. Gribben David C. Taussig Department of Gastroenterology, Royal London Hospital, Barts and the London NHS Trust, and… 
2012
2012
Investigation into omacetaxine solution stability for in vitro study.
Omacetaxine is a natural product extract originating from Chinese medicine and finding therapeutic use as a potent… 
2011
2011
Longitudinal studies of SRC family kinases in imatinib- and dasatinib-resistant chronic myelogenous leukemia patients.
2011
2011
Outcome of treatment of chronic myeloid leukemia with second-generation tyrosine kinase inhibitors after imatinib failure.
2011
2011
Subcutaneous Omacetaxine in Chronic or Accelerated Chronic Myeloid Leukemia Resistant to Two or More Tyrosine-Kinase Inhibitors Including Imatinib,
Abstract 3761 Background Omacetaxine is a first-in-class, reversible, transient inhibitor of protein elongation that does not… 
2010
2010
Subcutaneous Omacetaxine (OM) Treatment of Chronic Phase (CP) Chronic Myeloid Leukemia (CML) Patients Following Multiple Tyrosine Kinase Inhibitor (TKI) Failure
Abstract 2290 Introduction: Multiple TKI failure is a growing problem in a subset of CML patients. Treatment with a third TKI… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)